Stockreport

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. - American Depositary Shares  (CLLS) 
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: cellectis.com/en/investors
PDF This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® [Read more]